Pluri Inc.
PLURPluri Inc. in brief
Pluri Inc. is a listed company in the Biotechnology industry, based in Israel. Its market value was $15 M on 29 October 2026, which makes it the 25,017th largest listed company in the world and the 260th largest in Israel on this site. In the year to June 2026 it had sales of $1 M and a net loss of $24 M. It employs about 92 people and Yaky Yanay is its chief executive. Its shares trade under the symbol PLUR (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Pluri Inc.
We are a biotechnology company leveraging our proprietary 3D cell expansion platform, which is supported by an in-house, industrial-scale cell manufacturing facility and operates in accordance with Good Manufacturing Practice standards on a self-declared basis. Our platform is designed to enable scalable, cost-efficient and reproducible expansion of human, plant and animal cells and supports cell-based products, services, therapeutics and related technologies across two primary application areas: (i) Human Health and Longevity and (ii) Foodtech and Bio-Farming.
We were incorporated in Nevada on May 11, 2001. Pluri Inc. has a wholly owned subsidiary, Pluri Biotech Ltd., which is incorporated under the laws of the State of Israel.
From the company's annual report filed with the US SEC: read the report
Pluri Inc. timeline
- 2001
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2003
- ✎Renamed Pluristem Life Systems IncFormerly Ai Software Inc.
- 2007
- ✎Renamed Pluristem Therapeutics IncFormerly Pluristem Life Systems Inc.
- 2022
- ✎Renamed Pluri Inc.Formerly Pluristem Therapeutics Inc.
- 2025
- 💰Record revenue of $1 millionFY2025, the highest of the 8 years on record.
Events of Pluri Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Israel: #341 (Dec 2022) · #373 (Jul 2023) · #379 (Jan 2024) · #42 (Mar 2026) · #257 (Aug 2026) · #260 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 10.4×
- Price / book
- —
- Free cash flow yield
- -133.2%
- Net margin (TTM)
- -1942.5%
- Operating margin
- -2445.1%
- Return on equity
- —
- Liabilities / assets
- 170.1%
- Revenue growth
- -23.9%
- R&D / revenue
- 1479.4%
- Revenue per employee
- $11 K
- Profit per employee
- $-259 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Jun 2026 | $1M | -23.9% | $-25M | $-24M | -2335.3% |
| Jun 2025 | $1M | +306.1% | $-22M | $-23M | -1685.1% |
| Jun 2024 | $0M | +13.8% | $-22M | $-21M | -6330.3% |
| Jun 2023 | $0M | +26.1% | $-27M | $-28M | -9765.5% |
| Jun 2022 | $0M | — | $-42M | $-41M | -17930.4% |
| Jun 2021 | — | — | $-51M | $-50M | — |
| Jun 2020 | $0M | -60.0% | $-29M | $-29M | -145750.0% |
| Jun 2019 | $0M | — | $-36M | $-35M | -70620.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Jun 2026 | $-20M | $1M | $-20M | $-2.44 | — |
| Jun 2025 | $-18M | $2M | $-20M | $-3.56 | — |
| Jun 2024 | $-18M | $0M | $-18M | $-3.99 | — |
| Jun 2023 | $-23M | $0M | $-23M | $-6.24 | — |
| Jun 2022 | $-37M | $0M | $-37M | $-1.28 | — |
| Jun 2021 | $-31M | $0M | $-31M | $-1.77 | — |
| Jun 2020 | $-26M | $0M | $-27M | $-1.60 | — |
| Jun 2019 | $-29M | $0M | $-30M | $-2.90 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $1M (+137.5% on a year earlier), net income $-10M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Oct 30, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Other events
- Oct 20, 20268-KCurrent reportMaterial agreement · Unregistered share sale
- Oct 6, 2026S-1IPO registration
- Sep 10, 202610-KAnnual report · period to Jun 2026
- Aug 28, 20268-KCurrent reportMaterial agreement · Unregistered share sale
- Aug 17, 20268-KCurrent reportOther events
- Jul 14, 20268-KCurrent reportOther events
- Jul 13, 20268-KCurrent reportListing notice
- Jun 22, 20268-KCurrent reportMaterial agreement · Directors or officers changed · Shareholder vote
- Jun 1, 20268-KCurrent reportOther events
- May 14, 202610-QQuarterly report · period to Mar 2026
Official filings of Pluri Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $1 M
- Operating income
- $-25 M
- Net income
- $-24 M
For year ending June-2026 · source: SEC filing
Balance sheet
- Total assets
- $25 M
- Total liabilities
- $42 M
- Total equity
- $-23 M
As of June-2026
Top 18 institutional investors in Pluri Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Armistice Capital, LLC | 1,200,077 | New | 9.72% | $1 M | Nov 16, 2026 |
| 2 | Citadel Advisors LLC | 46,164 | New | 0.37% | $0 M | Nov 16, 2026 |
| 3 | Renaissance Technologies LLC | 16,056 | -2,268 (-12.38%) | 0.13% | $0 M | Nov 12, 2026 |
| 4 | Morgan Stanley | 2,982 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 5 | EverSource Wealth Advisors, LLC | 2,000 | 0 (0.00%) | 0.02% | $0 M | Nov 4, 2026 |
| 6 | UBS Group AG | 504 | -1,414 (-73.72%) | 0.00% | $0 M | Nov 10, 2026 |
| 7 | Barclays PLC | 366 | New | 0.00% | $0 M | Nov 6, 2026 |
| 8 | SIMA Wealth Partners, LLC | 350 | 0 (0.00%) | 0.00% | $0 M | Oct 19, 2026 |
| 9 | Wells Fargo & Company/mn | 185 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 10 | Jpmorgan Chase & Co | 125 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 11 | Royal Bank Of Canada | 125 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 12 | SBI Securities Co., Ltd. | 97 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 13 | TD Waterhouse Canada Inc. | 93 | -2 (-2.11%) | 0.00% | $0 M | Oct 16, 2026 |
| 14 | Activest Wealth Management | 86 | 0 (0.00%) | 0.00% | $0 M | Oct 15, 2026 |
| 15 | Osaic Holdings, Inc. | 50 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 16 | Winch Advisory Services, LLC | 26 | 0 (0.00%) | 0.00% | $0 M | Nov 6, 2026 |
| 17 | TFC Financial Management, Inc. | 19 | 0 (0.00%) | 0.00% | $0 M | Oct 26, 2026 |
| 18 | IFG Advisory, LLC | 13 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
Mutual funds holding Pluri Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 2,751 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Dimensional International Small Cap ETFDimensional Fund Advisors LP | 1 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 2 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Pluri Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Alexandre Weinstein ManieuDirector, 10% owner | Buyindirect | +833,334 | $1.500 | $1.3 M | 2.08 M | Form 4 |
| filed | Alexandre Weinstein ManieuDirector, 10% owner | Option exercise | +641 | — | — | 7,566 | Form 4 |
| filed | Alexandre Weinstein ManieuDirector, 10% owner | Grant or award | +180,000 | — | — | 190,769 | Form 4 |
| filed | Doron ShorrerDirector | Grant or award | +31,569 | — | — | 38,228 | Form 4 |
| filed | Alexandre Weinstein ManieuDirector, 10% owner | Grant or award | +641 | — | — | 6,925 | Form 4 |
| filed | Alexandre Weinstein ManieuDirector, 10% owner | Grant or awardindirect | +312,500 | $2.000 | $625 K | 1.25 M | Form 4 |
| filed | Alexandre Weinstein ManieuDirector, 10% owner | Grant or awardindirect | +312,500 | $2.000 | $625 K | 937,500 | Form 4 |
| filed | Chutzpah Holdings Ltd10% owner | Grant or awardindirect | +625,000 | $2.000 | $1.3 M | 625,000 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Pluri Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-05-19 13:32 UTC, code LUDP, resumed 13:37 UTC
- 2026-02-13 19:24 UTC, code LUDP, resumed 19:29 UTC
- 2025-09-10 15:26 UTC, code LUDP, resumed 15:31 UTC
- 2025-08-22 19:55 UTC, code LUDP, resumed 20:00 UTC
- 2025-06-23 18:57 UTC, code LUDP, resumed 19:07 UTC
Fails to deliver
- : 3,359 shares at $1.23
- : 501 shares at $1.12
- : 152 shares at $1.01
- : 324 shares at $1.25
- : 101 shares at $1.26
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Pluri Inc. scorecard#
Passes 3 of the 17 checks that could be worked out: strongest in growth (3 of 5), weakest in valuation (0 of 5). Fiscal year 2026; market cap of Oct 29, 2026.
Valuation0 of 5
Growth3 of 5
Profitability0 of 2
Financial health0 of 4
Shareholder returns0 of 1
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Pluri Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2026to Jun 30, 2026 | FY 2025to Jun 30, 2025 | FY 2024to Jun 30, 2024 | FY 2023to Jun 30, 2023 | FY 2022to Jun 30, 2022 | FY 2021to Jun 30, 2021 | FY 2020to Jun 30, 2020 | FY 2019to Jun 30, 2019 | FY 2018to Jun 30, 2018 | FY 2017to Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 1.0 | 1.3 | 0.3 | 0.3 | 0.2 | — | 0.0 | 0.1 | 0.1 | — | |
| Cost of revenue | 0.6 | 0.7 | 0.0 | 0.0 | — | — | — | 0.0 | 0.0 | — | |
| Gross profit | 0.5 | 0.7 | 0.3 | 0.3 | 0.2 | — | 0.0 | 0.1 | 0.0 | — | |
| Research and development | 15 | 13 | 12 | 16r | 25 | 31 | 23 | 30 | 26 | 24 | |
| General and administrative | 10 | 10.0 | 10 | 12 | 17 | 21 | 7.9 | 9.2 | 11 | 6.9 | |
| Operating income | −25 | −22 | −22 | −27 | −42 | −51 | −29 | −36 | −34 | −28 | |
| Interest and finance income | 0.5 | 1.1 | 1.4 | — | — | — | — | — | — | — | |
| Interest expense and finance costs | 0.9 | 0.9 | 0.9 | 0.8 | 0.9 | 0.1 | — | — | — | — | |
| Other non-operating income (expense) | −0.5 | −1.1 | 0.8 | −1.6 | 0.2 | 0.8 | 0.3 | 0.2 | 7.6 | 0.2 | |
| Income before tax | −25 | −23 | −21 | — | — | — | — | — | — | — | |
| Income tax | −0.0 | −0.0 | — | — | — | — | — | — | — | — | |
| Net income including minority interests | −25 | −23 | −21 | −29 | −41 | −50r | — | — | — | — | |
| Minority interests' share of net income | −1.5 | −0.7 | −0.5 | −0.6 | −0.1 | — | — | — | — | — | |
| Net income attributable to shareholders | −24 | −23 | −21 | −28 | −41 | −50 | −29 | −35 | −26 | −28 | |
| Earnings per share, basic | -2.44 | -3.56 | -3.99 | -6.24r | -1.28 | -1.77 | -1.60 | -2.90 | -2.50r | -3.20r | |
| Earnings per share, diluted | -2.44 | -3.56 | -3.99 | -6.24r | -1.28 | -1.77 | -1.60 | -2.90 | -2.50r | -3.20r | |
| Shares, weighted average (basic) | 9.7 | 6.3 | 5.2 | 4.6r | 32 | 28 | — | — | — | — | |
| Shares, weighted average (diluted) | 9.7 | 6.3 | 5.2 | 4.6r | 32 | 28 | 18 | 12 | 11r | 8.7r | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 3.5 | 5.9 | 6.8 | 5.4 | 9.8 | 31 | 8.3 | 4.1 | 8.8 | 4.7 | |
| Short-term investments | — | — | — | — | — | 34 | 38 | 20 | 21 | 6.2 | |
| Receivables | — | — | — | — | 0.0 | 0.0 | — | — | 0.1 | 1.0 | |
| Other current assets | 0.8 | 0.8 | 0.8r | 1.0 | 1.7 | 1.8 | 2.1 | 2.0 | 1.4r | 1.3 | |
| Current assets | 8.7 | 22 | 31 | 41 | 58 | 67 | 48 | 26 | 32 | 29 | |
| Property, plant and equipment | 1.6 | 1.8 | 0.7 | 0.7 | 0.7 | 1.5 | 2.5 | 3.8 | 5.7 | 7.3 | |
| Right-of-use (leased) assets | 6.2 | 6.9 | 6.6 | 7.6 | 8.3 | 0.7 | 1.3 | — | — | — | |
| Goodwill | 3.1 | 3.1 | — | — | — | — | — | — | — | — | |
| Other intangible assets | 2.6 | 2.8 | — | — | — | — | — | — | — | — | |
| Long-term investments | — | — | — | — | — | 23 | 12r | 0.4 | 0.4 | 0.4 | |
| Non-current assets | 16 | 17 | 8.4 | 9.4 | 10 | 26 | 17 | 4.9 | 6.9 | 8.5 | |
| Total assets | 25 | 39 | 40 | 51 | 68 | 94 | 66 | 31 | 39 | 38 | |
| Accounts payable | 0.7 | 0.9 | 1.0 | 1.8 | 1.8 | 2.5 | 2.0 | 2.3 | 3.3 | 2.0 | |
| Current liabilities | 33 | 32 | 4.5 | 5.6 | 6.8 | 12 | 8.0 | 8.2 | 8.5 | 5.4 | |
| Long-term debt | — | — | — | — | — | — | 1.3 | — | — | — | |
| Lease liabilities (non-current) | 6.5 | 6.1 | 5.0 | 5.7 | 6.5 | 0.1 | 0.6 | — | — | — | |
| Non-current liabilities | 9.6 | 7.2 | 30 | 30 | 29 | 25 | 1.4 | 1.3 | 1.9 | 1.9 | |
| Retained earnings | −467 | −443 | −420 | −400 | −371 | −330 | −280 | −251 | −216 | −190 | |
| Shareholders' equity | −23 | −6.8 | 0.1 | 13 | 30 | 57 | 56 | 22 | 29 | 30 | |
| Minority interests | 5.6 | 6.0 | 5.3 | 1.9 | 2.1 | — | — | — | — | — | |
| Total equity | −17 | −0.9 | 5.4 | 15 | 32 | 57 | 56 | — | — | — | |
| Total liabilities and equity | 25 | 39 | 40 | 51 | 68 | 94 | 66 | 31 | 39 | 38 | |
| Shares outstanding | 11 | 7.9 | 5.4 | 5.2r | 33 | 32 | 25 | 15 | 11r | 97 | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.5 | 0.3 | 0.3 | — | — | — | — | — | — | — | |
| Share-based compensation | 3.7 | 2.1 | 2.6 | 4.0 | 8.9 | 14 | 2.6 | 5.1 | 6.5 | 3.7 | |
| Cash from operating activities | −20 | −18 | −18 | −23 | −37 | −31 | −26 | −29 | −21 | −22 | |
| Capital expenditure | −0.6 | −1.6 | −0.3 | −0.3 | −0.3 | −0.4 | −0.3 | −0.2 | −0.3 | −0.4 | |
| Acquisitions, net of cash acquired | — | — | — | — | — | −0.0 | −0.0 | — | — | — | |
| Cash from investing activities | 9.9 | 8.0 | 11 | 9.7 | 12 | −7.3 | −30 | 1.2 | 5.7r | 4.4r | |
| Shares issued | 5.1 | 9.6 | 0.1 | 8.0 | — | 37 | 58 | 23 | 19 | 16 | |
| Cash from financing activities | 7.0 | 9.5 | 8.8 | 8.0 | 7.5 | 61 | 61 | 24 | 20 | 16 | |
| Exchange-rate effect on cash | 0.0 | 0.2 | 0.0 | −0.0 | −3.2r | −0.1r | — | — | — | — | |
| Change in cash | −2.6 | −0.5 | 1.4 | −5.2 | −20 | 23 | 4.0 | — | 4.1 | −1.5 | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Pluri Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Yaky Yanay | $1.5 M | $577 K | $590 K | — |
| 2024Yaky Yanay | $741 K | $307 K | — | — |
| 2023Yaky Yanay | $2.6 M | −$238 K | — | — |
Source: SEC proxy statement (Form DEF 14A) · as of Jun 30, 2025
Events at Pluri Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 5 · Directors and officers 6 · Material agreement 10 · Unregistered share sale 9 · Shareholder vote 2
| Filed | What happened | Filing |
|---|---|---|
| Material agreementUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Delisting notice | 8-K | |
| Directors and officersMaterial agreementShareholder vote | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Delisting notice | 8-K | |
| Directors and officersMaterial agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Delisting noticeDirectors and officersShareholder vote | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officersMaterial agreementUnregistered share sale | 8-K | |
| Delisting notice | 8-K | |
| Delisting notice | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Oct 30, 2026
Acquisitions and funding#
1 acquisitions, $6 M paid where reported · 1 private funding rounds before listing
Businesses it acquired
| Acquired | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|
| Kokomodo Transaction | 2025 | — | $6 M | — | Annual report |
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2026 | $4 M | Private placement after listing | $2 to $10 million | 1 | options | SEC |
| Feb 2025 | $4 M | Private placement after listing | $2 to $10 million | 1 | equity, options | SEC |
| Dec 2022 | $8 M | Private placement after listing | $2 to $10 million | 14 | equity, options | SEC |
| Oct 2010 | $1 M | No. 1 | Under $2 million | 9 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its annual reports since 2010, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Pluri Inc. compares in Biotechnology
- Market cap$15 M · higher than 15% of 726
- Revenue$1 M · higher than 25% of 647
- Revenue growth-23.9% · higher than 29% of 438
- Price / sales10.4× · lower than 43% of 339
- FCF yield-133.2% · higher than 6% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Pluri Inc.🇮🇱 | $15 M | — | — | -23.9% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Oneness Biotech Co., Ltd.$520 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
Sources and freshness
- Market cap:
- Oct 29, 2026
- Annual results:
- For year ending June-2026
- Balance sheet:
- As of June-2026
- Employees:
- As of June 30, 2026
- Profile updated:
- Nov 21, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Pluri Inc.? Verify and update this profile — free
Show Pluri Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.